Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...